NVS Overview

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Wall Street analysts forecast NVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVS is127.75 USD with a low forecast of 112.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Novartis AG revenue for the last quarter amounts to 13.86B USD, increased 2.23

Novartis AG. EPS for the last quarter amounts to 1.24 USD, decreased -11.43

Novartis AG (NVS) has 75267 emplpoyees as of March 12 2026.

Today NVS has the market capitalization of 297.29B USD.